SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-021838
Filing Date
2022-11-03
Accepted
2022-11-03 16:03:48
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20221103.htm   iXBRL 8-K 61542
2 EX-99.1 sndx-ex99_1.htm EX-99.1 260506
3 GRAPHIC img199102934_0.jpg GRAPHIC 14374
  Complete submission text file 0000950170-22-021838.txt   476684

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20221103_lab.xml EX-101.LAB 13916
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20221103_pre.xml EX-101.PRE 10229
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20221103.xsd EX-101.SCH 2463
8 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20221103_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 221357861
SIC: 2834 Pharmaceutical Preparations